加科思-B(01167.HK)附屬獲亦莊國投注資1.5億人幣
加科思-B(01167.HK)公佈,其全資附屬加科思(香港)、間接全資附屬北京加科思及公司首席執行官及董事會主席王印祥近期與亦莊國投訂立增資協議。據此,亦莊國投建議以現金出資1.5億元人民幣,認購北京加科思的額外註冊資本。
於增資完成後,北京加科思將由加科思(香港)擁有約96.97%及由亦莊國投擁有約3.03%。
公司指出,增資出資金額擬用於公司的KRAS G12C抑制劑以及其他創新項目的研發、生產及商業化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.